Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IL-12/IL12A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-12 Heterodimer (IL12A & IL12B) / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Native Glycosylation (HEK293). |
View IL-12/IL12A Products |
| Gene Delivery | IL12A Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View IL-12/IL12A Products |
| Benchmark Ab | Anti-IL-12/IL12A (Sequence of Biosimilar) Recombinant positive control. Sequence Verified. |
View IL-12/IL12A Products |
| Validator | IL12A siRNA Set For knockdown verification and pathway analysis. |
View IL-12/IL12A Products |
| Related Target A | IL-12RB1 Primary receptor subunit for binding kinetic assays. |
View IL-12RB1 Products |
| Related Target B | IL23A Shares the p40 subunit with IL-12; essential for counter-screening and cross-reactivity checks. |
View IL23A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Structural Integrity of Heterodimer | Recombinant p35/p40 heterodimers co-expressed in HEK293 for native folding and glycosylation. |
| Endotoxin Interference in Immune Assays | Strict endotoxin control (<1EU/ug) ensuring no false-positive immune cell activation. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included with verified sequences. |
| False Positives | Validated siRNA included for specificity checks in mechanistic studies. |
Live IL-12/IL12A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-12/IL12A therapeutics is intensifying, with major players shifting focus from systemic administration to targeted Immunocytokines, Masked Prodrugs, and mRNA delivery. As first-generation systemic therapies demonstrated unacceptable toxicity profiles, the next wave of R&D is targeting Tumor Microenvironment (TME)-conditional activation and precise spatial delivery to harness IL-12's potent Th1-polarizing and NK cell-activating properties without peripheral immune hyperactivation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Immunocytokines | Cullinan Oncology, Palleon | Solid Tumors | Receptor Binding Assay (Need high-purity Heterodimer) |
| Masked Cytokines | Xencor, CytomX | Refractory Cancers | Cleavage Release Validation (Need structurally stable native proteins) |
| mRNA Therapeutics | Moderna, BioNTech | Intratumoral Oncology | Expression Verification (Need specific Benchmark Abs) |
| Monoclonal Antibody (Anti-p40) | Johnson & Johnson | Psoriasis, Crohn's Disease | Cross-reactivity Assay (Need IL-12 vs IL-23 selectivity panels) |